{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-26-000035","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2026-08-03T10:46:50+00:00","discovered_at":"2026-08-03T10:50:00.469575+00:00","generated_at":"2026-08-03T10:50:09.762292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Supernus Q2 revenue up 32% to $219.1M; raises FY guidance; announces merger with Indivior","bullets":["Total revenues $219.1M, +32% YoY; growth products revenue $175.7M, +52% YoY.","Qelbree net sales $89.2M (+15% YoY); GOCOVRI $37.6M (+2%); ONAPGO $13.5M; ZURZUVAE collab rev $35.4M.","Company raises full-year 2026 financial guidance.","Agreed to merge with Indivior in all-stock merger of equals, creating diversified CNS company.","ONAPGO second supplier regulatory submission on track for Q3 2026, potential FDA approval by mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-26-000035","json":"https://secwatch.observer/filing/0001356576-26-000035.json","markdown":"https://secwatch.observer/filing/0001356576-26-000035.md","text":"https://secwatch.observer/filing/0001356576-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000035/0001356576-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000035/supn-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T10:50:09.762292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}